Collectively, these results show that the radiosensitivity of NPC cells is increased by the antiproliferative activity of pharmacologic RPA inhibition both in vitro and in vivo, suggesting its potential clinical application alongside radiotherapy in the management of cases with NPC. The gene discussed is RPA1; the disease is nasopharyngeal carcinoma.